Generics account for an ever-growing share of the pharmaceuticals sold in the competitive German market. The public health funds covering around 85% of the population pay less than one third of the price of original branded products for the generics they supply, so doctors in clinics and private surgeries are obliged to prescribe generics rather than branded originals whenever possible.
With many drugs worldwide set to lose patent protection in the near future, Germany’s generics market is forecasted to expand even further. Nevertheless it represents a difficult competitive environment for generic drugmakers, as discount agreements, rebate deals and frequent tenders create a high level of complexity. Moreover, there are a large number of generic players, triggering fierce competition and large price differentials. Bearing this situation in mind, the trading performance of Aurobindo Pharma GmbH is more than satisfactory.
“Since our foundation in 2009, we have gained the 19th place among Germany’s generics suppliers, which makes us the fastest-growing business in our field,” points out Managing Director Alexander Fiedel. “Leveraging India’s globally competitive cost base and talented team of scientists, we are able to successfully launch a whole range of competitive products in Germany. The recent acquisition of Aktavis Deutschland GmbH & Co. KG in Munich will also enhance our existing product portfolio.”
“Leveraging India’s globally competitive cost base and talented team of scientists, we are able to successfully launch a whole range of competitive products in Germany.” Alexander Fiedel managing director
Aurobindo Pharma GmbH generates annual sales in the region of 33 million EUR today, a figure that is bound to rise in the course of the takeover. Globally operating Aurobindo Pharma itself was founded in 1986 by P.V. Ramaprasad Reddy, K. Nityananda Reddy and a small group of highly committed professionals guided by the vision of developing semi-synthetic penicillin.
It is this vision – and its realization – that has gained Aurobindo Pharma a place among the top ten companies in India in terms of consolidated revenues. Aurobindo Pharma has evolved into a knowledge-driven company manufacturing active pharmaceutical ingredients and formulation products. Its cost-effective manufacturing capabilities have facilitated its entry into the high-margin specialty generic formulations segment.
The formulation business is systematically organized and has a focused team for key international markets. The Indian enterprise exports to over 125 countries across the globe today with more than 70% of its revenues derived from international operations. Its customers include premium multinational companies.
“We are able to combine the benefits of a competitive, diversified product portfolio, technology and know-how for specialty formulations, and vertical integration with the enthusiasm of a young and dynamic team.” Alexander Fiedel managing director
In addition to being the market leader in semi-synthetic penicillin, Aurobindo Pharma has a presence in other key therapeutic segments including neurosciences, cardiovascular ailments, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.
Aurobindo Pharma GmbH in Unterschleißheim focuses on 54 of the 400 different formulations available at present, covering indications of the heart and circulatory system, urology and the reproductive system, the central nervous system, virus treatment, metabolism, hypertension and diabetes.
“We are treading new ground with generics for the treatment of HIV at present, a pioneering development that is fully in line with Aurobindo Pharma’s mission of becoming one of the world’s most valued pharmaceutical partners by continuously researching, developing and manufacturing a wide range of pharmaceutical products that comply with the highest regulatory standards,” points out Mr. Fiedel. “We support this mission and the group strategy of working with local people abroad. We are able to combine the benefits of a competitive, diversified product portfolio, technology and know-how for specialty formulations, and vertical integration with the enthusiasm of a young and dynamic team.”